Time (UTC+8) Topic Speaker Moderator Abstract Slides Live streaming
16:50 - 17:00 Registration
17:00 - 17:50 Abstract oral presentation
17:50 - 18:00 Registration
18:00 - 18:10 [TBCS-GBCC Joint Session] Opening
Shou-Tung Chen
Ling-Ming Tseng
Shou-Tung Chen
Ling-Ming Tseng
18:10 - 18:40 [TBCS-GBCC Joint Session] Overcome the gap between the reality and international guideline: Korea’s view
Ai Ri Han
Ai Ri Han
18:40 - 19:10 [TBCS-GBCC Joint Session] Overcome the gap between the reality and international guideline: Taiwan’s view
Hsu-Huan Chou
Hsu-Huan Chou
19:10 - 20:10 [TBCS-GBCC Joint Session] Round table discussion
Chun-Yu Liu
Chi-Cheng Huang
Shou-Tung Chen
Yen-Shen Lu
Chiun-Sheng Huang
Hung-Wen Lai
Ling-Ming Tseng
Fang-Ming Chen
Shin-Cheh Chen
Ai Ri Han
Hsu-Huan Chou
Young-Joon Kang
Kyong Hwa Park
Kyung-Hun Lee
Inhae Park
Fang-Ming Chen
Chun-Yu Liu
Chi-Cheng Huang
Hung-Wen Lai
Young-Joon Kang
Kyong Hwa Park
Kyung-Hun Lee
Inhae Park
20:10 - 20:20 [TBCS-GBCC Joint Session] How to cooperate to enpower our voice
Chun-Yu Liu
Chi-Cheng Huang
Shou-Tung Chen
Yen-Shen Lu
Chiun-Sheng Huang
Hung-Wen Lai
Ling-Ming Tseng
Fang-Ming Chen
Shin-Cheh Chen
Ai Ri Han
Hsu-Huan Chou
Young-Joon Kang
Kyong Hwa Park
Kyung-Hun Lee
Inhae Park
Shin-Cheh Chen
Yen-Shen Lu
Chiun-Sheng Huang
Ai Ri Han
Young-Joon Kang
Kyong Hwa Park
20:20 - 20:30 [TBCS-GBCC Joint Session] Closing
Ling-Ming Tseng
Ling-Ming Tseng
Time (UTC+8) Topic Speaker Moderator Abstract Slides Live streaming
08:05 - 08:15 Registration
08:15 - 08:30 Opening Remark
Shou-Tung Chen
Pi-Sheng Wang
Shou-Tung Chen
Pi-Sheng Wang
08:30 - 09:00 What can we contribute to breast cancer in Taiwan ?
Mien-Chie Hung
King-Jen Chang
Hong-Tai Chang
09:00 - 09:30 Genetic testing for hereditary breast cancer - what we’ve learned today and what to do tomorrow in Taiwan?
Wen-Ling Kuo
Yuan-Ching Chang
Chia-Herng Yue
09:30 - 10:00 To whom should adjuvant PARP inhibitors be offered?
Charles E. Geyer
Chiun-Sheng Huang
Hung-Wen Lai
10:00 - 10:30 Coffee Break
10:30 - 11:00 The changing treatment landscape for HR+HER2-mBC patient with CDK4/6i
Dejan Juric
Ling-Ming Tseng
Yi-Fang Tsai
11:00 - 11:30 Treatment options with CDK4&6inhibitor, S-1, and PARP-inhibitor for HR-positive HER2-negative early breast cancer: Japan experience
Hiroko Masuda
King-Jen Chang
Guo-Shiou Liao
11:30 - 11:50 Mucinous carcinoma of the breast
Yoon-Sim Yap
Wen-Hung Kuo
Chih-Chiang Hung
11:50 - 12:20 Metaplatic carcinoma of breast: biology, challenges, and strategic direction
Ching-Hung Lin
Chen-Hsiang Chang
Yao-Jen Chang
12:20 - 13:00 [Luncheon Symposium] Thinking outside of the box? What are the possible options for metastatic breast cancer
Wei-Wu Chen
Tsu-Yi Chao
Kuo-Ting Lee
13:00 - 13:30 Break
13:30 - 14:00 Maximizing clinical benefit of atezolizumab in triple negative breast cancer
Chun-Yu Liu
Ming-Shen Dai
Dah-Cherng Yeh
14:00 - 14:30 The Benefit of Extended Adjuvant Therapy in HER2+ eBC Patients with High Recurrence Risk
Diana Lüftner
Fang-Ming Chen
Ta-Chung Chao
14:30 - 15:00 New horizon of TNBC: clinical outcomes and perspective of A Novel Trop-2 Antibody-Drug conjugate
Hope S. Rugo
Yen-Shen Lu
Chiao Lo
15:00 - 15:30 Coffee Break
15:30 - 16:00 Raising the bar for patients with HR+/HER2- Early Breast Cancer
Nadia Harbeck
Ming-Yang Wang
Chiun-Sheng Huang
16:00 - 16:30 Unsolved questions in CDK4/6i mBC setting
Fatima Cardoso
Shin-Cheh Chen
Chieh-Han Chuang
16:30 - 17:00 HER2 dual blockade treatment benefit on eBC patient survival and Singapore experience with FlexCare
Soo Chin Lee
Shyr-Ming Sheen-Chen
Shih-Che Shen
17:00 - 17:30 Past, present and future of HER2+ breast cancer treatment
Paul Cornes
Liang-Chih Liu
Chung-Chin Yao
Time (UTC+8) Topic Speaker Moderator Abstract Slides Live streaming
08:10 - 08:20 Registration
08:20 - 08:50 Local-regional management after neoadjuvant therapy - surgeon’s view
Laura Dominici
Jyh-Cherng Yu
Huan-Ming Hsu
08:50 - 09:20 Recent progress of antibody-drug conjugate in breast cancer treatment
Shanu Modi
Kun-Ming Rau
Chia-Ming Hsieh
09:20 - 09:50 Identify unmet needs for improving care for patients with chemotherapy-induced neutropenia
Chi-Cheng Huang
Shou-Tung Chen
Yuan-Chiang Chung
09:50 - 10:20 Recent advances in HER2 directed therapy in HER2 positive advanced breast cancer
Soo Chin Lee
Ming-Feng Hou
Ming-Hsin Yeh
10:20 - 11:00 Coffee Break
11:00 - 11:30 Experience sharing: how do we initiate and conduct large scale IIT
Jee Hyun Kim
Hsien-Kun Chang
Chun-Yu Liu
11:30 - 12:00 Local therapy for the primary site in De Novo Stage IV breast cancer
Seema A. Khan
Dar-Ren Chen
Shih-Hsin Tu
12:00 - 12:30 New Strategic Approach of Neoadjuvant in Early Breast Cancer
Chin-Sheng Hung
Yao-Lung Kuo
Shen-Liang Shih
12:30 - 13:10 [Luncheon Symposium] Recent Roles of Vacuum assisted breast biopsy in Korea
Sang-Won Kim
Fiona Tsui-Fen Cheng
Frank Fu Ou-Yang
13:10 - 13:20 Break
13:20 - 13:50 Bone-targeted agents for the management of breast cancer patients with bone metastases
Dwan-Ying Chang
Hsien-Tang Yeh
Tsen-Long Yang
13:50 - 14:10 Pseudocirrhosis: a unique presentation of liver metastasis in advanced breast cancer
Wei-Li Ma
Cheng-Ping Yu
Zhi-Jie Hong
14:10 - 14:20 Coffee Break
14:20 - 14:50 Neoadjuvant chemotherapy backbone, which is the optimal option?
Sibylle Loibl
Ming-Feng Hou
Chi-Cheng Huang
14:50 - 15:20 The considerations about adjuvant treatment choices after neoadjuvant therapy
Giampaolo Bianchini
Shin-Cheh Chen
Chien-Liang Liu
15:20 - 15:50 Avoiding breast and axillary surgery after neoadjuvant therapy
Joerg Heil
Chao-Ming Hung
Chin-Yao Lin
15:50 - 16:20 Adjuvant radiotherapy after neoadjuvant treatment
Boon H. Chua
Sung-Hsin Kuo
Chin-Hua Tsai
16:20 - 16:40 Panel Discussion
Sibylle Loibl
Giampaolo Bianchini
Joerg Heil
Boon H. Chua
Wei-Pang Chung
Jiun-I Lai
Yen-Dun Tzeng
Ling-Ming Tseng
Ming-Shen Dai
16:40 - 17:05 Award Ceremony & Closing
Shou-Tung Chen
Shou-Tung Chen